Literature DB >> 21996646

Thyroid adverse effects of psychotropic drugs: a review.

Rami Bou Khalil1, Sami Richa.   

Abstract

OBJECTIVES: Because many patients with mental illness take more than one psychotropic drug, an understanding of the effects of every class of these drugs is very important to manage any thyroid abnormalities that can happen with these patients.
METHODS: A systematic review of all the published literature was made via Medline. Keywords used for the search were "thyroid side effects" in association with one of the following: "antipsychotics," "antidepressants," "lithium," "anticonvulsants," "benzodiazepines," "anticholinergics," "antihistaminergics," "cholinesterase inhibitors," "stimulants," "methadone," and "naltrexone."
RESULTS: Phenothiazines, which are antipsychotics, mainly alter iodine capture, complex and deactivate it, as well as decrease thyroid-stimulating hormone's (TSH's) response to thyroid-releasing hormone (TRH). Nonphenothiazines, typical antipsychotics, can induce the formation of thyroid autoantibodies and can elevate TSH levels. Atypical antipsychotics may decrease TRH-stimulated TSH. Tricyclic antidepressant drugs complex with iodine and thyroid peroxidase and deactivate them, induce deiodinase activity and interfere with the hypothalamo-pituitary-thyroid (HPT) axis by decreasing TSH response to TRH. The main effect with other antidepressant drugs is a decrease in circulating thyroid hormone levels. Lithium inhibits thyroid hormone release and increases TRH-stimulated TSH, inducing goiter, clinical and subclinical hypothyroidism, and hyperthyroidism. Carbamazepine mainly reversibly decreases serum thyroid hormone levels. Other psychotropic drugs such as valproic acid, benzodiazepines, opiates, anticholinergic and antihistaminergic drugs, and stimulants have minor interferences with thyroid functions.
CONCLUSION: Patients receiving lithium, phenothiazines, and tricyclic antidepressants TCA should be closely monitored for the development of thyroid function abnormalities. Only patients at risk for developing thyroid function abnormalities should be monitored when they receive typical and/or atypical antipsychotic drugs, nontricyclic antidepressant drugs, and carbamazepine. No specific recommendations are proposed as toward thyroid function monitoring for patients receiving any other psychopharmacologic drug.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21996646     DOI: 10.1097/WNF.0b013e31823429a7

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  27 in total

1.  Trends in laboratory test volumes for Medicare Part B reimbursements, 2000-2010.

Authors:  Shahram Shahangian; Todd D Alspach; J Rex Astles; Ajay Yesupriya; William K Dettwyler
Journal:  Arch Pathol Lab Med       Date:  2013-06-05       Impact factor: 5.534

2.  Depressive symptoms, thyroid hormone and autoimmunity in a population-based cohort from Sardinia.

Authors:  Alessandro P Delitala; Antonio Terracciano; Edoardo Fiorillo; Valeria Orrù; David Schlessinger; Francesco Cucca
Journal:  J Affect Disord       Date:  2015-11-26       Impact factor: 4.839

3.  Lithium-induced transient euthyroid hyperthyroxinemia: a case report.

Authors:  Lakshminarayana Chekuri; Jaquelyn R Lange; Purushottam B Thapa
Journal:  Prim Care Companion CNS Disord       Date:  2014

4.  Differential effects of glycogen synthase kinase 3 (GSK3) inhibition by lithium or selective inhibitors in the central nervous system.

Authors:  Laura Caberlotto; Lucia Carboni; Floriana Zanderigo; Filippo Andreetta; Michela Andreoli; Gabriella Gentile; Maria Razzoli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-06-22       Impact factor: 3.000

5.  Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorder.

Authors:  Daniel A Gorman; David M Gardner; Andrea L Murphy; Mark Feldman; Stacey A Bélanger; Margaret M Steele; Khrista Boylan; Kate Cochrane-Brink; Roxanne Goldade; Paul R Soper; Judy Ustina; Tamara Pringsheim
Journal:  Can J Psychiatry       Date:  2015-02       Impact factor: 4.356

Review 6.  The bidirectional relation between psychiatric disorders with selected cardiovascular and endocrinal diseases: an Egyptian perspective.

Authors:  Tarek Okasha; Ash-Shayma Radwan
Journal:  Curr Psychiatry Rep       Date:  2015-01       Impact factor: 5.285

7.  Association of high BMI with subclinical hypothyroidism in young, first-episode and drug-naïve patients with major depressive disorder: a large-scale cross-sectional study.

Authors:  Chuanyi Kang; Jiacheng Liu; Yue Zheng; Xiaohong Wang; Liying Yang; Siyu Qiu; Ying Zhao; Blake N Lackey; Hanjing Emily Wu; Na Zhao; Xiangyang Zhang
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-05-12       Impact factor: 5.270

8.  The link between schizophrenia and hypothyroidism: a population-based study.

Authors:  Kassem Sharif; Shmuel Tiosano; Abdulla Watad; Doron Comaneshter; Arnon D Cohen; Yehuda Shoenfeld; Howard Amital
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

9.  Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment.

Authors:  Chadi A Calarge; Ginger Nicol; Janet A Schlechte; Trudy L Burns
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-04       Impact factor: 2.576

Review 10.  Pituitary side effects of old and new drugs.

Authors:  Maria Chiara Zatelli; Maria Rosaria Ambrosio; Marta Bondanelli; Ettore Degli Uberti
Journal:  J Endocrinol Invest       Date:  2014-07-29       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.